HeartSciences Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $4.3K | $4.4K | $18.6K | $5.2K | $14.4K |
| Cost of Revenue | $1.8K | $1.9K | $6.1K | $2.8K | $7.9K |
| Gross Profit | $2.6K | $2.5K | $12.5K | $2.4K | $6.5K |
| Gross Margin | 59.1% | 56.8% | 67.3% | 45.7% | 45.1% |
| Operating Expenses | |||||
| Research & Development | $2.8M | $4.4M | $2.9M | $2.5M | $3.0M |
| SG&A Expense | $5.6M | $4.0M | $3.4M | $3.7M | $1.7M |
| Operating Income | $-8.4M | $-8.4M | $-6.3M | $-6.1M | $-4.7M |
| Operating Margin | -194,787.4% | -192,013.1% | -33,902.0% | -118,698.3% | -32,765.6% |
| Interest Expense | — | — | $354.1K | $243.2K | $371.6K |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | — | — | — |
| Net Income | $-9.1M | $-8.8M | $-6.6M | $-6.4M | $-4.8M |
| Net Margin | -211,666.5% | -201,499.5% | -35,511.9% | -123,384.3% | -33,592.6% |
| EPS (Basic) | $-3.48 | $-3.11 | $-2.08 | $-2.22 | $-0.04 |
| EPS (Diluted) | — | $-3.11 | $-2.08 | $-2.22 | $-0.04 |
| Shares Outstanding (Basic) | 2.6M | 2.8M | 3.2M | 2.9M | 119.5M |
| Shares Outstanding (Diluted) | 2.6M | 2.8M | 3.2M | 2.9M | 119.5M |
| Dividends Per Share | $0.00 | $0.00 | — | — | — |